Potential targeted therapy for pediatric brain cancer identified by Dana-Farber team
Dana-Farber Cancer Institute researchers found that certain highly aggressive and currently incurable pediatric high-grade gliomas respond to avapritinib an FDA-approved targeted therapy.
2025-03-20
(Press-News.org)
Boston – An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma. They found that the drug, already FDA-approved for certain adult cancers, was generally safe and resulted in tumor reduction visible on brain scans, as well as clinical improvement, in 3 out of 7 patients.
The study was published in Cancer Cell.
Pediatric-type high-grade gliomas are currently incurable brain tumors with median survival times less than 18 months after initial diagnosis.
Avapritinib is a small molecule that crosses the blood-brain-barrier and targets platelet derived growth factor alpha (PDGFRA), which is overactive in some pediatric high-grade gliomas and leads to uncontrolled growth of cancer cells. The team is now designing a clinical trial of avapritinib treatment for newly diagnosed pediatric patients with PDGFRA-altered high-grade gliomas to evaluate it in a larger patient population.
“In a highly aggressive disease with no effective targeted treatment options currently available, we were excited to observe a radiographic and clinical response in a subset of mostly relapsed, highly treatment-refractory patients following monotherapy with an oral small-molecule inhibitor,” says lead senior author Mariella Filbin, MD, PhD, Jan Paradise Chair in Brain Cancer Research, co-director of the Brain Tumor Center of Excellence at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and research director of the Pediatric Neuro-oncology Program at Dana-Farber.
Filbin’s research team first identified that gene alterations activate PDGFRA in about 15% of pediatric high-grade glioma patients and contribute to the aggressive behavior of this disease, which is typically treated with surgery and radiation.
Efforts to target PDGFRA in high-grade glioma in the past were unsuccessful, most likely due to suboptimal pharmaco-kinetics and -dynamics of the drugs used. Avapritinib is a next-generation, highly selective and brain penetrant PDGFRA inhibitor. In pre-clinical research, Filbin’s team found that avapritinib reduced tumor growth in patient derived tumor models and animal models. Those results inspired them to collaborate with clinical partners at the University of Michigan and the Medical University of Vienna to treat patients a small group of patients with PDGFRA-altered high-grade glioma with avapritinib through a compassionate use program.
“It was truly inspiring to witness how our scientific research could be rapidly translated into clinical practice, directly benefiting patients,” says co-first author Sina Neyazi, MD, a postdoctoral fellow in the Filbin lab. “This discovery was made possible by the dedication of our clinical collaborators and the immense trust from patients and their families.”
Filbin’s team will next investigate which genetic alterations in tumors can predict response to avapritinib treatment, aiming to develop personalized treatment. Additionally, the team is developing combination therapies that include avapritinib alongside other FDA-approved drugs to maximize therapeutic effects and prevent treatment resistance.
“As a physician it is heartbreaking to tell a family that their child’s tumor has returned despite standard-of-care therapy,” says Filbin. “Our latest findings with brain-penetrant PDGFRA inhibitor avapritinib are encouraging for a subset of our patients who have genetic alterations in PDGFRA, and I am hopeful it will pave the way for developing innovative combination treatments that include avapritinib.”
Funding: Sajni Chakrabarti Fund for Pediatric Brain Cancer Research, Caroline Mortimer Fund, DMG Precision Medicine Collaborative, Claudia Adams Barr Program, Cuming Family Fund for Pediatric Brain Tumor Research, Anita, Sophia, and Athena Fund to Advance DIPG Research and Care, Liv Like A Unicorn, We love you Connie Fund, MaleiaStrong Foundation, The Morris Family, the DIPG All-In Initiative, the National Institutes of Health, the Burroughs Wellcome Fund, the Sontag Foundation, the Helen Gurley Brown Foundation, Alex’s Lemonade Stand Foundation, the Department of Defense, University of Michigan Chad Carr Pediatric Brain Tumor Center, Evans Family, ChadTough Defeat DIPG Foundation, Catching Up with Jack, Pediatric Brain Tumor Foundation, Michael Miller Memorial Foundation, Morgan Behen Golf Classic, and Yuvaan Tiwari Foundation, Forschungsgesellschaft fuer cerebrale Tumore and Verein unser_kind, the Medical University of Vienna, the Medical-scientific fund of the Mayor of the federal capital Vienna, the Austrian Science Fund, Ministry of Health of the Czech Republic, the German Research Foundation, Cancer Research UK, CRIS Cancer Foundation and Brain Tumour Research.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-03-20
POMs are a class of inorganic metal-oxygen cluster compounds with broad-spectrum antitumor potential. However, their strong hydrophilicity and poor lipophilicity result in insufficient cell membrane permeability, and high doses are required to achieve therapeutic effects, which severely limits their clinical application. To address this challenge, the research team proposes a covalent modification strategy: the construction of an amphipathic drug molecule PPT-POM-PPT by linking the hydrophobic anti-tumor drug Podophyllotoxin (PPT) with hydrophilic POMs. This molecule ...
2025-03-20
Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles. These rhythms are orchestrated by the suprachiasmatic nucleus (SCN) in the hypothalamus and involve a network of genes, including CLOCK and BMAL1, that influence metabolism, immune responses, and cell proliferation. Recent research has highlighted the crucial role of circadian rhythms in tumor biology, demonstrating that their dysregulation contributes to tumorigenesis, progression, and metastasis. Additionally, circadian rhythms influence the tumor immune microenvironment and the ...
2025-03-20
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis. Emerging research suggests that flavonoids, a diverse group of plant-derived polyphenols, may offer therapeutic potential in managing T2DM. These compounds exert antidiabetic effects through multiple mechanisms, including improving insulin sensitivity, enhancing β-cell function, modulating ...
2025-03-20
INDIANAPOLIS -- A large scale study by researchers from the Regenstrief Institute and the Indiana University School of Medicine has found that patient pain upon arrival to the Emergency Department (ED) as well as the use of hallway beds and radiology studies in the ED are associated with patient experience, although not in the same ways.
The study’s tens of thousands of observations including clinical and operational data revealed that regardless of how promptly or successfully pain was treated in the ED, the amount of pain the patient was in when they arrived was associated with patient experience ...
2025-03-20
Giving a second life to construction materials after demolition, engineers at the University of São Paulo and Princeton have developed an approach for recycling cement waste into a sustainable, low-carbon alternative that is comparable in performance to the industry standard.
In addition to lowering the carbon intensity of the cement and concrete industry, the process could enable new uses for construction and demolition waste, of which concrete is a significant component. In 2018 in the United States, the total ...
2025-03-20
Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV treatment, achieving high rates of sustained virologic response (SVR) and reducing HCV-associated morbidity and mortality. Despite these advancements, the risk of HCC persists in certain populations, particularly those with pre-treatment cirrhosis or advanced fibrosis (F3). This review examines the ...
2025-03-20
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT) to support the development and mechanistic understanding of safe and accessible next-generation engineered cell therapies for people with lupus. Engineered cell therapies, such as CD19-targeted chimeric antigen receptor (CAR) T cells, involve reengineering a patient’s own T cells to recognize and attack cells that cause disease.
The LRA established this program to build upon the promise already shown for engineered cell therapies in treating and potentially curing lupus, including ...
2025-03-20
Washington, D.C.—Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, and most likely other tick-borne diseases as well. The finding was reported in mBio, a journal of the American Society for Microbiology.
Lyme disease is the most commonly reported tick-borne illness in the United States and Europe. Its causative pathogen, Borrelia burgdorferi, has evolved unique metabolic pathways to cope with its enzootic life cycle, ...
2025-03-20
Two different teams of astronomers have detected oxygen in the most distant known galaxy, JADES-GS-z14-0. The discovery, reported in two separate studies, was made possible thanks to the Atacama Large Millimeter/submillimeter Array (ALMA), in which the European Southern Observatory (ESO) is a partner. This record-breaking detection is making astronomers rethink how quickly galaxies formed in the early Universe.
Discovered last year, JADES-GS-z14-0 is the most distant confirmed galaxy ever found: it is so far away, its light took 13.4 billion years to reach us, meaning we see it as it was when the Universe was less than 300 million years old, about 2% of its present age. ...
2025-03-20
Media Contact:
John Dudley
(814) 490-3290 (cell)
jjdudley@usf.edu
Images and a PDF of the journal article are available here
The study is the first to identify viruses associated with Karenia brevis, the single-celled organism that causes red tide
The findings are an initial step toward exploring viruses as biocontrol agents for red tide
TAMPA, Fla. (March 18, 2025) – A new study led by researchers at the University of South Florida shines light on the environmental drivers of red tide blooms.
Published in the American Society for Microbiology’s journal mSphere, ...
LAST 30 PRESS RELEASES:
[Press-News.org] Potential targeted therapy for pediatric brain cancer identified by Dana-Farber team
Dana-Farber Cancer Institute researchers found that certain highly aggressive and currently incurable pediatric high-grade gliomas respond to avapritinib an FDA-approved targeted therapy.
